Daiwa Securities Group
PDLI

Daiwa Securities Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Daiwa Securities Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-525
Closed -$15K – 939
2014
Q1 		$15K Buy
+525
New +$4.5K ﹤0.01% 870

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Daiwa Securities Group's PDLI Position: Q3 2020 in Review

Daiwa Securities Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 644 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in PDLI in Q1 2014 and held it in 12 quarters. The position peaked at $1.7M in Q1 2014. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Daiwa Securities Group reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Daiwa Securities Group sold 644 PDL BioPharma, Inc. shares in Q3 2020, an estimated $2K.
  • Daiwa Securities Group first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 12 quarters.
  • Daiwa Securities Group's PDL BioPharma, Inc. position peaked at $1.7M in Q1 2014.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Daiwa Securities Group's 13F filing for Q3 2020, filed 2 Nov 2020.